Insider Purchases: Inside the Buy

Tag: risks buying PFE

Editorial illustration depicting a physician reviewing Pfizer's financial outlook alongside biotechnology imagery, DNA strands, oncology research, dividend metrics, insider buying indicators, and rising valuation charts.

💊 Pfizer (PFE): Why a Former Vanguard CEO Just Bought Nearly $1 Million of This 6.4% Dividend Stock

Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.

Read entire article

Tags: AlbertBourla, Biotech, buy or sell PFE, Deep Value, Dividend Investing, Dividend Stocks, FUNanc1al, GLP-1, Healthcare, Healthcare Stocks, HighDividend, Insider Buying, Insider Purchases, Long-Term Investing, MortimerBuckley, Oncology, PFE, Pfizer, Pharmaceuticals, Rare Diseases, risks buying PFE, Ronald Blaylock, Seagen, Tim Buckley, Vaccines, Value Investing, ValueInvesting, Vanguard, why buy PFE